CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 21 enrolled / 21 target
Drug / intervention
Aspirin +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02521285
NCT02521285Phase 2ActiveUpdate Overdue (0.2/mo)Completion was 84mo ago
CompareCT.gov

Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation

National Cancer Institute (NCI)·interventional·Posted Aug 13, 2015·Updated Jun 17, 2026

In Brief

A Phase 2 clinical trial evaluating Aspirin, Laboratory Biomarker Analysis, and 2 other interventions for Barrett Esophagus and Esophageal Adenocarcinoma. Active but no longer recruiting, targeting 21 participants across 10 sites in 2 countries.

Signals

Enrollment appears stalled

Detailed Summary

This randomized phase II trial studies the safety of and how well aspirin works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether aspirin can prevent it from returning after it has been successfully treated.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBarrett Esophagus, Esophageal Adenocarcinoma
CountriesCanada, United States
Collaborators--

Timeline

Phase 2Active
201620172018201920202021202220232024202520262027
First PostedAug 13, 2015
Enrollment StartJan 15, 2016
Primary CompletionJun 18, 2019
Study CompletionMar 30, 2027
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 10.9 years ago

Arms & Interventions

Arm A (aspirin)experimental

Patients receive aspirin PO QD for 12 months.

Drug: AspirinOther: Laboratory Biomarker AnalysisOther: Questionnaire Administration
Arm B (placebo)placebo_comparator

Patients receive placebo PO QD for 12 months.

Other: Laboratory Biomarker AnalysisOther: Placebo AdministrationOther: Questionnaire Administration

Interventions

Aspirindrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies

Placebo Administrationother

Given PO

Questionnaire Administrationother

Ancillary studies